The results of the multivariate analysis indicated that the number of metastatic tumors (HR 2.46, P < 0.001), cN stage (P < 0.001), KRAS mutation (HR1.66, P < 0.05), BRAF mutation (HR 4.58, P < 0.001), age (HR 1.62, P < 0.05), primary tumor site (HR 1.61, P < 0.05), neutrophil count (HR 1.80, P < 0.05), platelet count (HR 2.53, P < 0.05), and D-Dimer levels (HR 1.62, P < 0.05) were the factors significantly associated with OS (Table 2). The gene discussed is KRAS; the disease is metastatic neoplasm.